U.S. FDA Accepts NDA And Grants Priority Review For Takeda's Oveporexton (Tak-861) As A Potential First-In-Class Therapy For Narcolepy Type 1

Takeda Pharmaceutical

10/02/2026 08:00

Takeda Pharmaceutical Co Ltd 4502.T:

TAKEDA PHARMACEUTICAL CO LTD - U.S. FDA ACCEPTS NDA AND GRANTS PRIORITY REVIEW FOR TAKEDA'S OVEPOREXTON (TAK-861) AS A POTENTIAL FIRST-IN-CLASS THERAPY FOR NARCOLEPY TYPE 1

Source text: ID:nTSnj870bc

Further company coverage: 4502.T